Peak Bio, Inc. (PKBO)
OTCMKTS
· Delayed Price · Currency is USD
0.0225
0.00 (0.00%)
Inactive · Last trade price
on Nov 14, 2024
Peak Bio Revenue
Peak Bio had revenue of $354.02K in the twelve months ending June 30, 2024, down -24.30% year-over-year. In the year 2023, Peak Bio had annual revenue of $367.88K, down -39.46%.
Revenue (ttm)
354.02K
Revenue Growth
-24.30%
P/S Ratio
6.92
Revenue / Employee
12.53K
Employees
6
Market Cap
520.31K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 367.88K | -239.80K | -39.46% |
Dec 31, 2022 | 607.68K | 79.37K | 15.02% |
Dec 31, 2021 | 528.31K | - | - |
Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPeak Bio News
- 3 months ago - SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO - Accesswire
- 11 months ago - Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari - PRNewsWire
- 11 months ago - Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit - GlobeNewsWire
- 1 year ago - Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing - GlobeNewsWire
- 1 year ago - Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicing - GlobeNewsWire
- 1 year ago - Peak Bio, Inc. Announces Up-listing to OTCQB Market - GlobeNewsWire
- 1 year ago - Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors - GlobeNewsWire
- 1 year ago - Peak Bio, Inc. Announces Amendment and Continued Access to Equity Line of up to $100 Million USD via an Accelerated Common Stock Purchase Transaction with White Lion Capital - GlobeNewsWire